Abstract
8077 Background: RTB at disease progression (PD) is increasingly used to profile tumor biomarkers and identify drug resistance mechanisms. However, information on safety and clinical consensus on t...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
